Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/BIIB
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Biogen Inc (BIIB) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Biogen (BIIB) trades at $212.50, down 3.77% over 24 hours, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q2 2026 EPS of $3.60, exceeding expectations, and has strong cash flow from operations of $2.20B in 2025. Positive developments include the approval of LEQEMBI in China and clinical data for zorevunersen, supporting growth prospects in neurology treatments.
The outlook is positive with a consensus price target of $241.06, indicating 13% upside, driven by pipeline progress and acquisitions like RayThera. Risks include declining net income margins and competitive pressures in multiple sclerosis drugs. Institutional buying, such as BlackRock's $3.45B stake in Q2 2026, underscores confidence, but investors should monitor execution on new drug launches.
Read full analysis

Key Stats

  • Market Cap
    $31.40B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $224.51
  • 52W Low
    $135.67
  • Typical Hold Time
    -
  • Enterprise Value
    $38.47B
  • Div Yield
    -
  • Trading Activity
    -
$212.5
52W Low: $135.67
25 Sep 2025
52W High: $224.51
03 Sep 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $135.67 and a high of $224.51, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Most Recent News

Content is generated by Aura AI

US private employers added 12,000 jobs weekly on average in August, showing hiring acceleration.

For the four weeks ending August 22, 2026, US private employers added an average of 12,000 jobs per week, according to ADP's National Employment Report Pulse. This figure shows an acceleration in hiring compared to previous weeks, reflecting a positi...

Market News
4 hours ago
PRNewsWire
Neutral
US private employers added 12,000 jobs weekly on average in August, showing hiring acceleration.

Five top dividend stocks trade near 52-week lows, offering high yields for patient investors.

Five well-known dividend-paying companies—Clorox, Comcast, Duke Energy, General Mills, and VICI Properties—are currently trading near their 52-week lows, presenting attractive opportunities for income-focused investors. These stocks offer high divide...

Market News
4 hours ago
24/7 Wall Street
Bullish
news icon
Five top dividend stocks trade near 52-week lows, offering high yields for patient investors.

Inhibrx advances cancer drugs with FDA review for ozekibart due by April 2027

Inhibrx is progressing its cancer treatments ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets. Ozekibart showed a 52% risk reduction in chondrosarcoma progression and strong responses in colorectal and Ewing sarcoma, ...

Market News
4 hours ago
Seeking Alpha
Bullish
news icon
Inhibrx advances cancer drugs with FDA review for ozekibart due by April 2027
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $31.40B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $224.51
  • 52W Low
    $135.67
  • Typical Hold Time
    -
  • Enterprise Value
    $38.47B
  • Div Yield
    -
  • Trading Activity
    -
$212.5
52W Low: $135.67
25 Sep 2025
52W High: $224.51
03 Sep 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $135.67 and a high of $224.51, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!